| Recruiting | Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN281 NCT06980038 | National Cancer Institute (NCI) | Phase 2 |
| Not Yet Recruiting | Reduced Elective Nodal and CTV Dose for HPV+ Oropharyngeal Squamous Cell Carcinoma NCT07497607 | Sara Medek | Phase 2 |
| Not Yet Recruiting | Lattice-Based Radiotherapy and Chemoimmunotherapy for Oropharyngeal Squamous Cell Carcinoma NCT07428148 | NYU Langone Health | Phase 1 / Phase 2 |
| Not Yet Recruiting | Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReAC NCT07513324 | Dana-Farber Cancer Institute | Phase 2 |
| Not Yet Recruiting | A Single Arm Phase II Trial in p16-positive Oropharynx Cancer of Selective Dose De-escalation of nodAl VolumEs NCT07418034 | University of Maryland, Baltimore | Phase 2 |
| Not Yet Recruiting | SPECT-CT Guided ELEctive Contralateral Neck Treatment in Lateralized Oropharyngeal Cancer NCT07241273 | UNICANCER | N/A |
| Not Yet Recruiting | Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer NCT07058805 | Olgun Elicin | Phase 2 |
| Withdrawn | Saliva Testing for High-Risk Human Papillomavirus Infection Oral Cavity and Pharynx Cancer NCT06362421 | Wake Forest University Health Sciences | — |
| Recruiting | Shortened Course of Radiation Therapy After Trans-oral Robotic Surgery in Patients With HPV-Mediated Oropharyn NCT07044635 | University of Utah | Phase 2 |
| Recruiting | Dual-energy CT vs. MRI in the Evaluation of Squamous Cell Carcinomas of the Oral Cavity and Oropharynx NCT07343271 | University Hospital, Strasbourg, France | — |
| Not Yet Recruiting | Neoadjuvant and Adjuvant Sintilimab Plus Cetuximab in Locally Advanced Oral and Oropharyngeal Squamous Cell Ca NCT07079410 | Shanghai Zhongshan Hospital | Phase 2 |
| Not Yet Recruiting | Autologous T Cells Targeting HPV16 HPV18 & Survivin in Patients With R/R HPV-related Oropharyngeal Cancers NCT05582590 | NexImmune Inc. | Phase 1 |
| Recruiting | Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin a NCT06662058 | Emory University | N/A |
| Recruiting | People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity NCT06055868 | University of California, San Francisco | — |
| Recruiting | Validity of Viome's Oral/throat Cancer Test NCT06174428 | Viome | — |
| Recruiting | Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy f NCT06532279 | NRG Oncology | Phase 2 |
| Recruiting | Comparing an Investigational Scan (F-18 NaF PET/CT) to Standard of Care Imaging (F-18 FDG PET/CT) for Evaluati NCT06914999 | Emory University | EARLY_Phase 1 |
| Completed | Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyn NCT06771674 | Hookipa Biotech GmbH | — |
| Withdrawn | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carbopl NCT06084845 | ECOG-ACRIN Cancer Research Group | Phase 2 |
| Recruiting | Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer NCT06323460 | Ohio State University Comprehensive Cancer Center | Phase 2 |
| Recruiting | Personalized Elective Neck Irradiation Guided by Sentinel Lymph Node Biopsy in Larynx and Pharynx Cancer. The NCT05333523 | Radboud University Medical Center | Phase 3 |
| Active Not Recruiting | Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT) NCT06009861 | Peking University Hospital of Stomatology | Phase 2 |
| Recruiting | The Registry Study of Genetic Alterations of Oropharyngeal Cancer in Taiwan NCT05522881 | National Health Research Institutes, Taiwan | — |
| Recruiting | The Role of Circulating Tumour DNA in Head and Neck Cancer NCT05539638 | University of Edinburgh | — |
| Recruiting | Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma NCT05268614 | University of Florida | Phase 2 |
| Recruiting | Three Schedules of CUE-101 Administered Before Surgery or Definitive Chemoradiation Therapy in HLA-A*0201 Posi NCT04852328 | Washington University School of Medicine | Phase 2 |
| Completed | Ex Vivo 3D-ultrasound for Oropharyngeal Cancer NCT06314711 | Rigshospitalet, Denmark | N/A |
| Recruiting | Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Orophary NCT05098119 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Terminated | Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Ca NCT04801472 | Institut de cancérologie Strasbourg Europe | N/A |
| Active Not Recruiting | Selective Avoidance of Nodal VolumEs at Minimal Risk (GCC 20110) NCT04609280 | University of Maryland, Baltimore | Phase 2 |
| Active Not Recruiting | Neoadjuvant Sintilimab in Combination With Carboplatin and Nab-paclitaxel in Resectable Oral Cavity or Orophar NCT04718415 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 |
| Active Not Recruiting | Post-treatment Surveillance in HPV+ Oropharyngeal SCC NCT04965792 | Dana-Farber Cancer Institute | — |
| Recruiting | Prospective Observational Study to Validate Circulating HPVDNA and Prognostic Genomic Biomarkers in HPV-associ NCT04564989 | UNC Lineberger Comprehensive Cancer Center | — |
| Completed | Pilot Study of Chemotherapy for HPV-Associated Oropharyngeal Cancer NCT04572100 | University of Chicago | Phase 1 |
| Recruiting | Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma NCT04220749 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Phase 2 |
| Unknown | Imaging of Tumour Microenvironment in Patients With Oropharyngeal Head and Neck Squamous Cell Carcinoma Using NCT04222543 | Radboud University Medical Center | Phase 2 |
| Recruiting | Oropharynx (OPX) Biomarker Trial NCT06356272 | Mayo Clinic | — |
| Active Not Recruiting | De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patien NCT03952585 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Withdrawn | Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Unde NCT03611205 | Ohio State University Comprehensive Cancer Center | N/A |
| Active Not Recruiting | Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal NCT07407205 | Institute of Oncology Ljubljana | N/A |
| Unknown | A New Mutational and Epigenetic Signature to Predict Early OPSCC Relapse NCT06138483 | Centro di Riferimento Oncologico - Aviano | — |
| Completed | Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous C NCT03623646 | Institut Claudius Regaud | Phase 2 |
| Completed | Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma NCT03618654 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | EARLY_Phase 1 |
| Terminated | Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Par NCT03618134 | Jonsson Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Foll NCT03410615 | Canadian Cancer Trials Group | Phase 2 |
| Completed | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck NCT03258554 | National Cancer Institute (NCI) | Phase 2 / Phase 3 |
| Unknown | Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell NCT03727594 | University Hospital of Ferrara | — |
| Terminated | Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck NCT02582008 | Wake Forest University Health Sciences | EARLY_Phase 1 |
| Suspended | Identification of Breath Biomarkers in Head and Neck Squamous Cell Carcinoma NCT02156180 | Queensland Centre of Excellence for Head and Neck Cancer | — |
| Completed | The Sinai Robotic Surgery Trial in HPV Positive Oropharyngeal Squamous Cell Carcinoma (SCCA) (SIRS TRIAL) NCT02072148 | Icahn School of Medicine at Mount Sinai | N/A |
| Unknown | Efficacy and Safety of TORS for SCCA NCT01819480 | Katherine L Fedder | N/A |
| Unknown | Determination of Cetuximab Versus Cisplatin Early and Late Toxicity Events in HPV+ OPSCC NCT01874171 | University of Warwick | Phase 3 |